Can I Take Creatine With NMN or NR (Nicotinamide Mononucleotide/Riboside)?

What Happens in the Body When You Take Both?

No published trial has studied NMN and creatine given together in the same arm, so the interaction picture is built from mechanistic reasoning plus independent human pharmacology data for each compound. The short answer: these two supplements work through entirely separate biochemical routes, share no common enzyme or transporter that would create a classical pharmacokinetic clash, and the only credible overlap is in how they both affect a single blood-test number, serum creatinine.

How NMN and NR Raise NAD+

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors. After oral ingestion, NR is taken up by cells via nucleoside transporters and phosphorylated to NMN by nicotinamide riboside kinase-1 and -2 (NRK1/2). NMN itself is converted to NAD+ by NMNAT enzymes in the cytosol and mitochondria. A 2018 randomized crossover trial (N=12) by Trammell et al. Published in Nature Communications confirmed that oral NR at 1,000 mg reliably raised whole-blood NAD+ metabolites within 2 to 3 hours. Neither conversion step touches the creatine-phosphocreatine system.

How Creatine Works

Creatine is taken up by skeletal muscle via the SLC6A8 transporter and phosphorylated to phosphocreatine by creatine kinase. Phosphocreatine donates its phosphate group to regenerate ATP during high-intensity effort. A fixed fraction of muscle phosphocreatine is non-enzymatically cyclized to creatinine each day and excreted by the kidneys. The 2017 International Society of Sports Nutrition (ISSN) position stand (Rawson et al.) confirmed that creatine monohydrate at 3 to 5 g/day is safe for long-term use in healthy adults and that the creatinine rise it produces reflects increased muscle substrate, not kidney damage.

Why the Two Pathways Do Not Collide

NMN/NR metabolism is confined to the pyridine nucleotide cycle: nicotinamide, NMN, NR, NAD+, NADH, and downstream methylated metabolites excreted in urine. Creatine metabolism runs through the separate guanidinoacetate-creatine-creatinine axis. These pathways share no rate-limiting enzyme, no shared transporter in intestinal or renal epithelium, and no common cytochrome P450 isoform. That means no competitive inhibition, no induction, and no protein-binding displacement, the three mechanisms that drive most pharmacokinetic drug interactions.

The Creatinine Lab Interference Problem

This is the one concern that deserves real clinical attention. Both creatine supplementation and (to a lesser degree) high-dose NMN/NR can push serum creatinine upward, and an uninformed clinician may misread the result as acute kidney injury or worsening chronic kidney disease.

Creatine's Effect on Creatinine

Creatine loading (20 g/day for 5 to 7 days) can raise serum creatinine by 20 to 30 µmol/L above baseline in some individuals. A systematic review by Pline and Smith (2005) in Pharmacotherapy found that creatine supplementation consistently elevates serum creatinine without accompanying rises in cystatin C or actual GFR decline, confirming the elevation is a metabolic artifact rather than a sign of renal dysfunction. Switching to the maintenance dose of 3 to 5 g/day typically blunts this rise.

NMN/NR's Effect on Creatinine

The picture for NMN/NR is less dramatic but real. A 10-week double-blind RCT of NMN 250 mg/day in healthy older adults (Yamaguchi et al., 2022) reported no significant change in serum creatinine vs. Placebo. However, higher doses (900 to 1,200 mg/day) used in some Phase I studies produced mild creatinine increases in a subset of participants, likely because NAD+ flux upregulates mitochondrial activity and, with it, muscle turnover. The signal is small but worth tracking when stacking with creatine.

What to Tell Your Doctor

If you are already stacking both supplements and your physician orders a metabolic panel, mention both compounds before the blood draw. Cystatin C is a creatinine-independent GFR marker and should be ordered whenever creatinine-based eGFR appears unexpectedly low in a supplement user. The National Kidney Foundation notes that cystatin C provides a more accurate GFR estimate than creatinine alone in people with unusual muscle mass or high creatine intake.

Evidence Base for Each Supplement Individually

Human Trials on NMN

A 2020 Phase I trial by Irie et al. (N=10) in npj Aging and Mechanisms of Disease demonstrated that single oral doses of NMN up to 500 mg were safe and well-tolerated, with dose-dependent increases in plasma NMN and NAD+ metabolites. No renal adverse events occurred. A separate 12-week RCT by Yi et al. (2023) tested NMN 300 mg/day in middle-aged adults and found improvements in muscle strength and gait speed, suggesting NAD+ restoration may complement the performance benefits of creatine rather than oppose them.

Human Trials on NR

Martens et al. (2018) ran a 6-week randomized crossover in older adults (N=30) using NR 500 mg twice daily and found NAD+ in peripheral blood mononuclear cells rose by roughly 60% vs. Baseline. Blood pressure fell modestly in the NR arm. Serum creatinine was monitored and did not change significantly at this dose, though eGFR was not the primary endpoint.

Human Trials on Creatine

The ISSN 2017 position stand reviewed more than 500 peer-reviewed papers on creatine monohydrate. Creatine at 3 to 5 g/day for up to 5 years showed no adverse renal, hepatic, or cardiovascular effects in healthy populations. Athletic populations using loading protocols (20 g/day for 7 days) showed transient creatinine elevation that normalized within 2 weeks of dropping to maintenance dosing.

Pharmacokinetic Timing: Do You Need to Separate Doses?

No. There is no pharmacokinetic basis for separating NMN/NR from creatine by time of day. They do not compete for the same intestinal transporters: creatine uses SLC6A8 (a sodium-chloride-dependent transporter expressed in the gut and muscle), while NR uses concentrative nucleoside transporters (CNTs) and equilibrative nucleoside transporters (ENTs). NMN may be partly dephosphorylated to NR in the gut before absorption, but even then, it enters a nucleoside-specific pathway that has no overlap with SLC6A8.

Morning vs. Post-Workout Dosing

In practice, most people take creatine post-workout alongside protein because muscle insulin sensitivity may slightly improve uptake, though the timing effect is modest. NMN and NR are often taken in the morning, partly on the hypothesis that NAD+ synthesis tracks circadian clock gene expression. Neither schedule conflicts with the other.

Co-administration Is Acceptable

Taking all three in a single morning dose, NMN or NR plus creatine, carries no interaction risk based on current mechanistic and clinical data. The decision can come down to personal tolerance and habit rather than pharmacology.

Potential Synergies Between NAD+ Precursors and Creatine

The following framework helps clinicians and patients think about why stacking NMN/NR with creatine might actually make sense from an energy-metabolism perspective, even though no RCT has tested the combination head-to-head.

The Dual Energy Currency Model

ATP production in muscle depends on two primary fast-recharge systems: the phosphocreatine buffer (replenished by creatine supplementation) and the NADH/NAD+ redox cycle (supported by NMN/NR). These systems run in parallel inside skeletal muscle cells.

• Creatine loading increases the phosphocreatine pool available for immediate ATP rephosphorylation during the first 10 to 30 seconds of maximal effort.
• NMN/NR supplementation raises NAD+ availability, which supports electron transport chain efficiency and sirtuin-mediated mitochondrial biogenesis over weeks to months.
• A working hypothesis: creatine covers short-burst energy demand; NMN/NR covers the mitochondrial quality and capacity dimension.

This theoretical complementarity does not substitute for a controlled trial, but it provides a plausible biological reason why athletes and longevity-focused individuals are increasingly stacking both. Clinicians reviewing the stack should evaluate it on its individual component safety data until combination RCT data become available.

Who Should Be More Careful

People With Pre-existing Kidney Disease

CKD patients already have reduced creatinine clearance. Adding creatine significantly increases creatinine production and may obscure worsening GFR. NMN/NR at standard doses (<500 mg/day) has not been studied in CKD cohorts. The FDA's guidance on dietary supplement safety notes that individuals with kidney disease should consult a physician before starting creatine or other supplements that alter nitrogen-containing metabolites. CKD patients who want NAD+ support may trial low-dose NR (250 mg/day) with cystatin C monitoring rather than a full NMN/creatine stack.

Older Adults

Serum creatinine naturally decreases with age because muscle mass declines. Creatine supplementation in older adults may normalize creatinine to a range that falsely appears elevated relative to their usual low baseline. A review by Candow et al. (2019) in Nutrients found that creatine 5 g/day combined with resistance training improved lean mass in adults over 55 without adverse renal effects. Baseline creatinine, cystatin C, and BUN before starting the stack give the clinician a meaningful reference point.

People on Nephrotoxic Medications

NSAIDs, aminoglycosides, certain antifungals, and calcineurin inhibitors all carry renal risk. Adding creatine while on any of these compounds may complicate the creatinine picture further. NMN/NR does not carry direct nephrotoxic risk in current data, but the metabolic load on the kidneys (methylated NAD+ breakdown products including MeNAM and Me-2PY are renally cleared) may still be worth factoring in when the renal reserve is already stressed.

Practical Dosing Guide for the Stack

The table below synthesizes current evidence for each compound individually. No head-to-head stacking trial yet specifies a combined optimal dose.

| Supplement | Starting Dose | Studied Upper Dose | Timing | Monitoring | |---|---|---|---|---| | NMN | 250 mg/day | 1,200 mg/day | Morning, with or without food | BMP at baseline and 4 to 8 weeks | | NR | 250 mg/day | 1,000 mg/day | Morning, with or without food | BMP at baseline and 4 to 8 weeks | | Creatine (maintenance) | 3 g/day | 5 g/day | Post-workout or any consistent time | BMP at baseline; cystatin C if creatinine rises | | Creatine (loading) | 5 g x 4 daily for 5 to 7 days | 20 g/day (loading phase only) | Divided with meals | BMP before and after loading phase |

Avoid the loading protocol if you have a baseline eGFR <60 mL/min/1.73m², and discuss any stacking plan with a prescribing clinician if your eGFR is <90.

What the Guidelines Say

No major guideline (American College of Sports Medicine, ISSN, or Endocrine Society) addresses the specific NMN/NR plus creatine combination, because no combination trial has generated data sufficient to prompt a formal statement. Each compound is evaluated independently.

The ISSN 2017 position stand states: "Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass during training." It explicitly notes that concerns about creatine's effects on kidney function in healthy adults are not supported by the evidence.

On the NAD+ precursor side, a 2023 consensus statement from a longevity-medicine working group published in GeroScience noted that NMN and NR supplementation in humans shows a favorable short-term safety profile at doses up to 1,000 mg/day, while calling for longer RCTs to characterize effects beyond 12 months.

Neither body has flagged an interaction between NAD+ precursors and creatine.

Summary Monitoring Protocol

For a healthy adult starting both supplements together, a three-step monitoring protocol is appropriate.

Step 1: Baseline labs before starting the stack. Order a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP). Record serum creatinine, BUN, eGFR, and if budget allows, cystatin C. This gives the clinician a reference point that predates any supplement-driven creatinine change.

Step 2: Recheck at 4 to 8 weeks. Repeat the BMP. A rise in serum creatinine of 20 to 40 µmol/L in the absence of any cystatin C change or BUN elevation is almost certainly supplement-related and not pathological. No dose change is required. A rise accompanied by a cystatin C increase, rising BUN, or new urinary symptoms warrants holding creatine and repeating labs in 1 to 2 weeks.

Step 3: Annual labs thereafter. Once stability is confirmed, yearly metabolic monitoring is sufficient for healthy adults with no CKD risk factors.